Safety, Efficacy, and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients
A Multicenter, Randomized, Open-Label, Parallel, Active-Comparator Trial to Determine the Efficacy, Safety, and Pharmacokinetics of Ibuprofen Injection in Pediatric Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85008
- Maricopa Medical Center
-
-
California
-
Loma Linda, California, United States, 92354
- Loma Linda University Medical Center
-
Orange, California, United States, 92868
- Children's Hospital of Orange County
-
-
District of Columbia
-
Washington DC, District of Columbia, United States, 20060
- Howard University
-
-
Florida
-
Miami, Florida, United States, 33136
- Jackson Memorial Hospital (U. Miami)
-
Orlando, Florida, United States, 32804
- Florida Hospital
-
-
Georgia
-
Augusta, Georgia, United States, 30909
- Joseph M. Still Burn Center
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Kosair Children's Hospital
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121-2483
- Ochsner Clinic Foundation
-
Shreveport, Louisiana, United States, 71103
- LSU Health Sciences Center
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Children's Hospital of Michigan
-
-
New York
-
Staten Island, New York, United States, 10305
- Staten Island University Hospital
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74136
- The Children's Hospital at Saint Francis
-
-
Tennessee
-
Memphis, Tennessee, United States, 38103
- LeBonheur Children's Hospital
-
-
Texas
-
Dallas, Texas, United States, 75235
- Children's Medical Center Dallas
-
Houston, Texas, United States, 77030
- Texas Children's Hospital
-
Houston, Texas, United States, 77030
- Children's Memorial Hermann Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have written informed consent provided by legal parent, guardian, or authorized agent prior to participation in the study or study-only related procedures.
- Be between birth (28 weeks to < 40 weeks gestational age) to ≤ 16 years of age.
- Have new (less than 7 days) onset of fever, documented by temperature greater than or equal to 101.0 ºF (38.3 ºC).
Exclusion Criteria:
- Have inadequate intravenous access.
- Have received antipyretic drug therapy within 2 hours before dosing.
- Have any history of allergy or hypersensitivity to NSAIDs or aspirin.
- Have received another investigational drug within the past 30 days.
- Be otherwise unsuitable for the study, in the opinion of the Investigator.
- Have a fever due to hyperthermia.
- Pregnant or nursing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: ibuprofen
Ibuprofen, 10 mg/kg
|
Ibuprofen, 10 mg/kg
|
|
ACTIVE_COMPARATOR: Acetaminophen
Acetaminophen, 10mg/kg
|
Acetaminophen, 10mg/kg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fever Reduction
Time Frame: 0 to 2 hours post-dose
|
Treatment of fever as measured by the area under the change in temperature versus time curve during the first two hours of treatment (AUC0-2)
|
0 to 2 hours post-dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Temperature After the First 30 Minutes of Treatment
Time Frame: 30 minutes following treatment
|
Change in temperature in patients receiving intravenous ibuprofen and acetaminophen (APAP) after the first 30 minutes of treatment.
|
30 minutes following treatment
|
|
Change From Baseline in Temperature After the First 60 Minutes of Treatment
Time Frame: 60 minutes following treatment
|
Change in temperature in patients receiving intravenous ibuprofen and APAP after the first 60 minutes of treatment.
|
60 minutes following treatment
|
|
Change in Temperature
Time Frame: 4 hours following treatment
|
Change in temperature in patients receiving intravenous ibuprofen and APAP after the first 4 hours of treatment.
|
4 hours following treatment
|
|
Change From Baseline in Temperature After the First Four Hours of Treatment
Time Frame: 0 to 4 hours post-dose
|
Change in temperature during the first 4 hours of treatment by assessing the area under the change in temperature versus time curve during the first four hours of treatment (AUC0-4)
|
0 to 4 hours post-dose
|
|
Time to Afebrility (in Hours)
Time Frame: 4 Hour post treatment
|
Tme to afebrility (temperature less than 100.4 ºF [38 ºC]) in patients receiving intravenous ibuprofen and APAP.
|
4 Hour post treatment
|
|
Number of Afebrile and Febrile Subject at 4 Hours Post-Dose
Time Frame: 4 Hours Post-Dose
|
Number of Afebrile and Febrile Subject at 4 Hours Following Treatment
|
4 Hours Post-Dose
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Art Wheeler, M.D., Cumberland Pharmaceuticals, Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Body Temperature Changes
- Fever
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Antipyretics
- Acetaminophen
- Ibuprofen
Other Study ID Numbers
Other Study ID Numbers
- CPI-CL-012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.